Detalles de la búsqueda
1.
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Invest New Drugs
; 39(3): 812-820, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33409898
2.
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Lancet Oncol
; 20(10): 1432-1443, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31515154
3.
Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.
Proc Natl Acad Sci U S A
; 113(45): 12786-12791, 2016 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27791181
4.
Pattern and Distribution of Distant Metastases in Anaplastic Prostate Carcinoma: A Single-Institute Experience With 101 Patients.
AJR Am J Roentgenol
; 209(2): 327-332, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28590819
5.
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 2024 Apr 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38683200
6.
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series.
Clin Cancer Res
; 30(10): 2272-2285, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38488813
7.
Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1.
JU Open Plus
; 2(4)2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38774466
8.
Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2.
JU Open Plus
; 2(4)2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38774467
9.
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
Eur Urol
; 83(3): 267-293, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36494221
10.
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Eur J Cancer
; 185: 178-215, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37003085
11.
Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components.
Cancers (Basel)
; 14(13)2022 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35805010
12.
Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis.
Cell Rep
; 39(1): 110595, 2022 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35385726
13.
Hypomethylating agents for urologic cancers.
Future Oncol
; 7(3): 447-63, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21417907
14.
Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer.
Cancers (Basel)
; 13(5)2021 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33801459
15.
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
J Immunother Cancer
; 9(10)2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34663638
16.
A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kß Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 27(19): 5248-5257, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34281912
17.
Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors.
JAMA Netw Open
; 4(8): e2122998, 2021 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34459906
18.
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
J Immunother Cancer
; 9(7)2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34326169
19.
Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.
Clin Cancer Res
; 26(15): 4143-4153, 2020 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32341031
20.
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer.
Clin Cancer Res
; 26(5): 990-999, 2020 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31941830